Hikal Receives Crisil ESG 65 Rating for FY26

Date: September 29, 2026

ESG Rating Disclosure

The rating was provided as per Crisil ESG Ratings' report dated September 28, 2026, and categorizes the company under the Pharmaceuticals sector.

ESG Rating Rationale

The ESG Rating Rationale highlights several areas where the company performed better than its peers:

Environmental Performance:

• Better performance in share of renewables in energy consumption mix
• High waste recycling rate of the total waste generated
• Relatively low water withdrawal from water stress areas

Social Performance:

• Better performance in employee skill upgradation and safety measures
• Low customer complaint intensity
• Nil stakeholder complaints
• Zero safety-related incidents
• Zero recalls

Governance Performance:

• Adequate Board strength
• High share of women directors on the Board
• High average attendance of independent directors at the Board and committee meetings
• Nil whistle blower complaints
• Nil investor complaints

Important Note

The company specifically states that it has not engaged Crisil ESG Ratings & Analytics Limited for this ESG Rating. The rating provider independently prepared the report based on data available in the public domain.